The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application

Yang, Qinzhi; Wang, Gang; Fang, Dan; Gao, Xiaojun; Yu, Liang; Wang, Liqun; Wu, Jianbo; Zeng, Min; Luo, Mao

doi:10.1016/j.biopha.2022.113130

Cited by 8 publications

(4 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its antihyperglycemic effect does not emerge if no insulin secretion occurs [ 28 ]. Of interest, metformin treatment is accompanied by a moderate reduction in body weight (3–4 kg) of the subjects and, in the long-term use, by a decrease in cardiovascular risk with favorable effects on vascular endothelium and antioxidant and anti-inflammatory actions [ 29 , 30 ]. A recent study of sex differences of metformin antihyperglycemic effect was evaluated in Chinese subjects treated for 24 and 48 weeks with this drug, showing a similar reduction in HbA1c between females and males [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi

2024

Pharmaceuticals

View full text Add to dashboard Cite

Metformin is a synthetic biguanide used as an antidiabetic drug in type 2 diabetes mellitus, achieved by studying the bioactive metabolites of Galega officinalis L. It is also used off-label for various other diseases, such as subclinical diabetes, obesity, polycystic ovary syndrome, etc. In addition, metformin is proposed as an add-on therapy for several conditions, including autoimmune diseases, neurodegenerative diseases, and cancer. Although metformin has been used for many decades, it is still the subject of many pharmacodynamic and pharmacokinetic studies in light of its extensive use. Metformin acts at the mitochondrial level by inhibiting the respiratory chain, thus increasing the AMP/ATP ratio and, subsequently, activating the AMP-activated protein kinase. However, several other mechanisms have been proposed, including binding to presenilin enhancer 2, increasing GLP1 release, and modification of microRNA expression. Regarding its pharmacokinetics, after oral administration, metformin is absorbed, distributed, and eliminated, mainly through the renal route, using transporters for cationic solutes, since it exists as an ionic molecule at physiological pH. In this review, particular consideration has been paid to literature data from the last 10 years, deepening the study of clinical trials inherent to new uses of metformin, the differences in effectiveness and safety observed between the sexes, and the unwanted side effects. For this last objective, metformin safety was also evaluated using both VigiBase and EudraVigilance, respectively, the WHO and European databases of the reported adverse drug reactions, to assess the extent of metformin side effects in real-life use.

show abstract

Section: Resultsmentioning

confidence: 99%

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi

2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Multiple studies have demonstrated that individuals diagnosed with type 2 diabetes who undergo long-term and high-dose treatment with metformin exhibit an exacerbation of DPN. This can be attributed to a reduction in cobalamin levels, as well as an elevation in homocysteine and methylmalonic acid concentrations [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Metformin Reduces the Risk of Diabetic Neuropathy Among Egyptian Type 2 Diabetic Patients: A Case-Control Study

Hicham,

Sayed,

Abdelsalam Besibes

et al. 2023

Archives of Pharmaceutical Sciences Ain Shams University

View full text Add to dashboard Cite

This study aimed to investigate the association of different patient factors with the occurrence of diabetic peripheral neuropathy (DPN) among type 2 diabetes mellitus patients. A case-control study was conducted on a total sample of 180 Egyptian type 2 diabetic patients. A full medical, medication, social, and family history was collected for the recruited sample. Glycated hemoglobin, lipid profile, and microalbuminuria were assessed. Among 180 patients recruited, 128 patients suffered from DPN. Low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were higher among patients suffering from DPN (p-value = 0.007 and 0.005, respectively). Metformin usage was the only factor that showed a significant decrease in the odds of developing DPN (odds ratio 0.511, 95% confidence interval 0.264-0.911). Subgroup analysis showed that metformin decreased DPN among males rather than females (p-value = 0.006 vs 0.616, respectively). In conclusion, Serum LDL-C and TC are both determinants for increased risk of DPN among type 2 diabetic patients. Metformin usage decreases DPN in a sex-specific dimorphic fashion where females are less liable to the protective effect of metformin against DPN.

show abstract

“… 93 miR-210-5p mimic inhibits the expression of PFKFB2, represses the process of glycolysis, and induces energy stress in pancreatic cancer. 94 miR-613 inhibits the expression of PFKFB2 by binding to the 3′ UTR of PFKFB2, thus significantly inhibiting gastric cancer cell growth, inhibiting colony-forming ability and cell invasion ( Figure 2 and Table S1 ). 95 …”

Section: Non-coding Rnas In Glucose Metabolismmentioning

confidence: 99%

Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease

Zong¹,

Wang²,

Cheng³

et al. 2023

Molecular Therapy

View full text Add to dashboard Cite

The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application

Cited by 8 publications

References 175 publications

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Metformin Reduces the Risk of Diabetic Neuropathy Among Egyptian Type 2 Diabetic Patients: A Case-Control Study

Decoding the regulatory roles of non-coding RNAs in cellular metabolism and disease

Contact Info

Product

Resources

About